Impact of immunosuppressive therapy on the severity of COVID-19 in solid organ transplant recipients

Minotti, 2020, How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection? A systematic review, J Infect, 10.1016/j.jinf.2020.04.026

Pereira, 2020, COVID-19 in solid organ transplant recipients: initial report from the US epicenter, Am J Transplant, 20, 1800, 10.1111/ajt.15941

Colmenero, 2020, Epidemiological pattern, incidence and outcomes of COVID-19 in liver transplant patients, J Hepatol

Webb, 2020, Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study, Lancet Gastroenterol Hepatol, 10.1016/S2468-1253(20)30271-5

Giamarellos-Bourboulis, 2020, Complex immune dysregulation in COVID-19 patients with severe respiratory failure, Cell Host Microbe, 10.1016/j.chom.2020.04.009

Horby, 2020, Dexamethasone in hospitalized patients with Covid-19 – preliminary report, N Engl J Med

Howell, 2013, Cyclosporine and tacrolimus have inhibitory effects on toll-like receptor signaling after liver transplantation, Liver Transpl, 19, 1099, 10.1002/lt.23712

Ni, 2020, Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals, Immunity, 52, 971, 10.1016/j.immuni.2020.04.023

2020, A minimal common outcome measure set for COVID-19 clinical research, Lancet Infect Dis, 20, e192, 10.1016/S1473-3099(20)30483-7

Alteri, 2020, Nasopharyngeal SARS-CoV-2 load at hospital admission as predictor of mortality, Clin Infect Dis